Key Player In The Interferons Market, Bayer AG, Collaborates With Curadev Pvt. Ltd.
Bayer AG and Curadev Pvt. Ltd., a drug discovery company based in India, have announced a research collaboration and license agreement for Curadev’s Stimulator of Interferon Genes (STING) antagonist program. The objective of this collaboration between Bayer and Curadev is to discover new drug candidates for the treatment of lung diseases, cardiovascular diseases, and other inflammatory diseases. STING antagonists have huge potential for new treatments as STING is known to help in activating the innate immune system in auto-inflammatory diseases.
The interferons market consists of sales of interferons, the biopharmaceuticals that are produced using living organisms, such as microorganisms and animal cells, and have a high-therapeutic value. The market consists of revenues generated by the establishments from sales of various types of interferons such as alpha interferons, beta interferons, and gamma interferons.
Major players in the global interferons market include Roche, Merck, Bristol-Myers Squibb, Biogen Inc, Bayer AG, Zydus Cadila, Novartis AG, Pfizer Inc, Biosidus, Nanogen, Amega Biotech, Rhein Minapharm Biogenetics, PROBIOMED, Schering-Plough Corporation., and 3Sbio. The global interferons market was valued at about $6.9 billion in 2019 and is expected to grow to $8.1 billion at a compound annual growth rate (CAGR) of 4% through 2023.
The interferons market is segmented by type into inteferon alpha, inteferon beta, and inteferon gamma. By application, it is segmented into hepatitis b, hepatitis c, melanoma, leukemia, multiple sclerosis, and renal cell carcinoma.
The global interferon drugs market is projected to grow at a rapid pace in the next few years due to the increasing incidence of chronic diseases such as hepatitis-B, hepatitis-C, cancer, and multiple sclerosis, among others, and the use of interferons in combinational therapies, and advent of novel drug delivery systems. Various types of interferon (IFN) have been used to treat these diseases, and an important development in treating some of these diseases was the recognition that the clinical effects of IFN drug could be greatly enhanced by combining it with other drugs. For instance, IFN-a (interferon-alpha) in combination with ribavirin and polyethylene glycol molecule has shown significant improvements in virological response, without any adverse effects. However, due to the poor stability of interferon-alpha in the gastrointestinal tract, only parenteral administration ensures bioavailability, which is associated with severe side effects. Studies showed that nanoencapsulation of IFN-a within nanoparticles would improve the oral bioavailability of this drug. The use of interferons in combinational therapies, and advent of novel drug delivery systems is therefore expected to drive the market for interferons. Interferons are also being tested for their use in the treatment of COVID-19.